/Companies

Tarveda Therapeutics

Watertown, US · Founded 2011 · Delaware corporation · 5 employees on LinkedIn · 3 known investors

Find your way into Tarveda Therapeutics

Sign up to see every warm intro you have to Tarveda Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Tarveda Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Founders & leadership

Tarveda Therapeutics was founded in 2011 by Omid Farokhzad, Robert S. Langer, Jr., and Robert S. Langer.

OFOmid Farokhzad
Omid FarokhzadCo-founderChair and Chief Executive Officer at Seer
RSRobert S. Langer, Jr.
Robert S. Langer, Jr.Co-founderScientific Advisory Committee Member at Polaris Partners
RSRobert S. Langer
Robert S. LangerCo-founderScientific Advisory Committee Member at Polaris Partners
AJ
Andrew J. FromkinExecutive
LA
Leila AllandChief Medical Officer2016–2018Leila Alland is an MD with extensive experience in oncology drug development at major pharmaceutical companies including AstraZeneca, Bristol-Myers Squibb, Novartis, and Schering-Plough, where she held leadership roles in clinical development and served as Chief Medical Officer at PMV Pharma, Affimed, and Tarveda Therapeutics. She holds a BA from the University of Pennsylvania and an MD from New York University, completed fellowship training in hematology/oncology at Memorial Sloan Kettering Cancer Center, and served as faculty at Albert Einstein College of Medicine.
RW
Richard WoosterPresident R&D and Chief Scientific Officer2016–2019

Board

JB
James BarrettBoard director
FT
Frank TortiBoard director
NK
Nilesh KumarBoard director
ASAymeric Sallin
Aymeric SallinBoard Member2011–2022Founder and CEO at +ND Capital
EM
Edwin M. KaniaBoard director
DA
Dennis AusielloBoard director

Investors · 3

Reported raises · per SEC filings

Form D private placements

$103.6M disclosed across 6 rounds · 2014–2021

▶$6MraisedSep 2021 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Aymeric SallinDirector
  • Michael MetzgerDirector
  • Brian RobertsExecutive Officer, Director
  • Nilesh KumarDirector
  • Dennis AusielloDirector
  • Guido MagniDirector
Offering amount
$6M
Amount sold
$6M
First sale
Sep 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15MraisedDec 2020 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Nilesh KumarDirector
  • Guido MagniDirector
  • Michael MetzgerDirector
  • Aymeric SallinDirector
  • Brian RobertsExecutive Officer
  • Dennis AusielloDirector
Offering amount
$15.4M
Amount sold
$15M
First sale
Dec 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$13.6MraisedDec 2019 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael MetzgerDirector
  • Aymeric SallinDirector
  • Robert LangerDirector
  • Nilesh KumarDirector
  • Guido MagniDirector
  • Omid FarokhzadDirector
  • Andrew J. FromkinExecutive Officer, Director
  • Dennis AusielloDirector
Offering amount
$13.6M
Amount sold
$13.6M
First sale
Dec 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$38MraisedFeb 2017 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Aymeric SallinDirector
  • Andrew FromkinExecutive Officer, Director
  • Robert S. LangerDirector, Promoter
  • Leila AllandExecutive Officer
  • Edwin M. KaniaDirector
  • James BarrettDirector
  • Dennis AusielloDirector
  • Nilesh KumarDirector
  • Richard WoosterExecutive Officer
  • Omid C. FarokhzadDirector, Promoter
  • Frank TortiDirector
Offering amount
$38M
Amount sold
$38M
Finders' fees
$720K
Proceeds to insiders
$2.5M
Placement agents
MTS Securities, LLC
First sale
Jan 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$30MraisedFeb 2017 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Andrew J. FromkinExecutive Officer, Director
  • Omid FarokhzadDirector
  • James BarrettDirector
  • Frank TortiDirector
  • Robert S. Langer, Jr.Director
  • Leila AllandExecutive Officer
  • Nilesh KumarDirector
  • Dennis AusielloDirector
  • Richard WoosterExecutive Officer
  • Aymeric SallinDirector
  • Guido MagniDirector
Offering amount
$30M
Amount sold
$30M
First sale
Jan 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1000KraisedMar 2014 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Omid C. FarokhzadDirector
  • Robert S. LangerDirector
  • James BarrettDirector
  • Richard WoosterExecutive Officer
  • Peter Barton HuttDirector
  • Aymeric SallinDirector
  • Edwin M. KaniaDirector
Offering amount
$1000K
Amount sold
$1000K
First sale
Feb 2014
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Tarveda Therapeutics went on to found or lead other companies.

Frequently asked questions

Who founded Tarveda Therapeutics?
Tarveda Therapeutics was founded by Omid Farokhzad, Robert S. Langer, Jr., Robert S. Langer in 2011.
Who are Tarveda Therapeutics's investors?
Tarveda Therapeutics's investors include +ND Capital, Kendall Capital Partners, New Enterprise Associates (NEA).
How much funding has Tarveda Therapeutics raised?
Tarveda Therapeutics has disclosed $103.6M raised across 6 rounds.
Where is Tarveda Therapeutics headquartered?
Tarveda Therapeutics is headquartered in Watertown, US.